



Advance in Genetic Research of Epilepsy

Guest Editor:

Dr. Antonietta Coppola

Department of Neuroscience,
Odontostomatology and
Reproductive Sciences,
University of Naples Federico II,
Naples, Italy

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Over the last two decades, the landscape of epilepsy genetics has increasingly grown thanks to the availability of advanced genetic testing. Many new genes have been linked to various types of epilepsy and especially developmental and epileptic encephalopathies (DEE). In addition, epilepsy has been linked with microCNVs defining specific syndromic conditions. Furthermore, although rarely, epilepsy has been linked to non-coding repeated expansion.

These genetic discoveries have improved our understanding of the molecular and cellular pathways involved in epilepsy, transforming our clinical practice. The most exciting implication is the possibility to provide new targets for the development of precision.

This Special Issue will cover the following research topics:

- Current use of genetic testing in clinical and research settings;
- Developmental and epileptic encephalopathies-associated genes;
- CNVs-associated epilepsies;
- Repeated expansion disorders and epilepsy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)